PET scan to predict response in bile duct cancer
Part of Cancer clinical trials.
This study tests whether a special PET scan (using [18F]FTT) can predict how well the standard GCD chemotherapy and immunotherapy combination will work for newly diagnosed bile duct cancer. The scan helps doctors see tumor activity before treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with bile duct cancer (cholangiocarcinoma)
- You have not yet received any treatment for this cancer
- Your doctor plans to treat you with gemcitabine, cisplatin, and durvalumab (GCD)
- You have at least one tumor that can be seen and measured on a CT or MRI scan
- You are 18 years old or older
- If you could become pregnant, you must have a negative pregnancy test and agree to use birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET-CT scan (called FAPI) to see if it helps doctors better decide treatment for people with bile duct cancer that can be surgically removed. It may help avoid unnecessary surgery if the scan shows the cancer has spread.
This trial tests a new imaging method called FAPI-PET to see if it can better detect pancreatic and bile duct cancers at an early stage. It may help doctors decide on the best treatment plan for you.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
This trial is testing a new type of PET scan (called 68Ga-FAPI) to see if it can better detect biliary tract cancers, including advanced or recurring gallbladder cancer and intrahepatic cholangiocarcinoma. It may help doctors find cancer more accurately, which could guide better treatment decisions.
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.